THE CHRONIC LYMPHOCYTIC LEUKEMIA TREATMENTS AND THEIR SUSTAINABILITY: A NOVEL PHARMACO-ECONOMIC MODEL (SIE 2026) - Oct 6, 2026 - Abstract #DP181; Pres time: Sep 22, 2026; 06:30 PM - 07:30 PM; Location: AREA POSTER; "A cost-effective- ness model was developed to compare BTKIs (ibrutinib, acalabrutinib, zanubrutinib) and fixed-duration regimens (obinutuzumab–venetoclax, ibrutinib–venetoclax) over 3- and 5-year time horizons. Both continuous and fixed-duration therapies for CLL are clinical- ly effective and economically sustainable. Integrating phar- macoeconomic evaluations into routine clinical practice can support more sustainable and patient-centered treatment de- cisions."
HEOR • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • BTK
|
|
S. Galimberti1; S. Lazzini2; K. Belvedere3; G. Fabbri3; S. Tallarico2; O. Vancheri4
|